Valanx Biotech

VALANX Biotech is an Austrian biotechnology company developing next‑generation antibody–drug conjugates (ADCs) for cancer therapy. Its proprietary GoldenSite™ platform enables precise, site‑specific attachment of cytotoxic payloads to antibodies, reducing off‑target toxicity and improving the therapeutic window of ADCs.

VALANX applies this technology to build both best‑in‑class ADC candidates and first‑in‑class therapeutic assets, while also partnering with pharmaceutical and biotechnology companies through platform licensing and development collaborations. 

The company was founded as a university spin‑out and is based in Vienna, where it combines advanced protein engineering with translational drug development.